Lates News

BioNTech (BNTX.US) continued to rise by about 8.5%, closing at $122.7. The stock surged over 18% yesterday. On the news front, Pfizer announced it had reached a milestone payment agreement with BioNTech on the new generation anti-cancer drug BNT327, with a maximum milestone payment of up to $11.1 billion. In addition, Truist Securities raised BioNTech's target price from $151 to $155, maintaining a "buy" rating.